Mascot Health Series Pvt Ltd sets new standard in diabetes care with DCGI approved Dapagliflozin, Glimepiride, and Metformin ER tablets

New Delhi : Mascot Health Series Pvt.Ltd has received the Drug Controller General of India’s (DCGI) approval for its triple combination diabetes treatment. Mascot claims to be the first CDMO to launch Dapagliflozin + Glimepiride + Metformin ER tablets for commercial consumption.

The drug combines Dapagliflozin, Glimepiride, and Metformin are said to provide better treatment without the need for multiple drugs.

The triple combination is a cost-effective and well-tolerated treatment option in patients with type-2 diabetes who are not able to achieve adequate glycemic control despite metformin–sulphonylurea combination treatment.

Commenting on the approval, Narender Kukreja, Managing Director, Mascot Health Series Pvt.Ltd, said, “At Mascot, we are committed to improving access to high-quality medicines that significantly improve health outcomes."

He further said, “Timely access to new and innovative treatment strategies for diabetes patients is essential in improving the quality of care and alleviating the burden of diabetes on the economy, society, and the wider community.

Asif Siddiqui, Vice President-Business Development In-Licensing of Mascot Health Series Pvt. Ltd informed that the company is now looking at strengthening its position in the domestic market and forging several value-accretive in-licensing agreements to manufacture and sell innovative products and to make the drugs accessible to Indian patients.